Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease

NCT07190196 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07190196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07190196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Recruiting
Start date
September 26, 2025
Completion date
December 25, 2030
Enrollment
124 (estimated)
Sites
92

Conditions

As the registry lists them; a condition with its own page is linked.

immunoglobulin g4 related disease